Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLK Allakos	$0.33	$0.33	$0.22 ▼ $1.56	$29.74M	0.15	1.24 million shs	N/A
GEMP Gemphire Therapeutics	$0.67 +0.9%	$4.97	$0.24 ▼ $1.49	$10.02M	2.82	127,174 shs	14,409 shs
HILS Hillstream BioPharma	$1.63 -3.0%	$1.53	$0.19 ▼ $2.65	$28.69M	3.08	1.39 million shs	45,536 shs
MRNS Marinus Pharmaceuticals	$0.55 -0.2%	$0.55	$0.22 ▼ $1.97	$30.32M	1.03	1.90 million shs	260 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLK Allakos	0.00%	0.00%	0.00%	+0.95%	-60.80%
GEMP Gemphire Therapeutics	-5.97%	+4.53%	-8.82%	-9.10%	-86.18%
HILS Hillstream BioPharma	-0.59%	-0.60%	+30.23%	+46.09%	-58.72%
MRNS Marinus Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	-62.77%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALLK Allakos	3.35 of 5 stars	3.1	0.0	0.0	4.7	0.0	2.5	1.3
GEMP Gemphire Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
HILS Hillstream BioPharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MRNS Marinus Pharmaceuticals	2.0525 of 5 stars	3.2	0.0	0.0	4.2	0.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLK Allakos	2.25	Hold	$2.00	507.72% Upside
GEMP Gemphire Therapeutics	0.00	N/A	N/A	N/A
HILS Hillstream BioPharma	0.00	N/A	N/A	N/A
MRNS Marinus Pharmaceuticals	2.40	Hold	$3.92	613.29% Upside

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLK Allakos	N/A	N/A	N/A	N/A	$1.93 per share	N/A
GEMP Gemphire Therapeutics	N/A	N/A	N/A	N/A	$0.54 per share	N/A
HILS Hillstream BioPharma	N/A	N/A	N/A	N/A	$0.48 per share	N/A
MRNS Marinus Pharmaceuticals	$30.99M	0.98	N/A	N/A	$0.31 per share	1.77

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLK Allakos	-$185.70M	-$1.32	N/A	N/A	N/A	N/A	-140.87%	-86.22%	8/6/2025 (Estimated)
GEMP Gemphire Therapeutics	-$23.64M	N/A	0.00	∞	N/A	N/A	-419.70%	-173.05%	N/A
HILS Hillstream BioPharma	-$8.47M	-$0.72	N/A	N/A	N/A	N/A	-188.44%	-149.61%	N/A
MRNS Marinus Pharmaceuticals	-$141.40M	-$2.47	N/A	N/A	N/A	-446.48%	-7,831.35%	-120.74%	8/11/2025 (Estimated)

Latest GEMP, MRNS, HILS, and ALLK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/6/2025	Q2 2025	ALLK Allakos	-$0.24	N/A	N/A	N/A	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLK Allakos	N/A	N/A	N/A	N/A	N/A
GEMP Gemphire Therapeutics	N/A	N/A	N/A	N/A	N/A
HILS Hillstream BioPharma	N/A	N/A	N/A	N/A	N/A
MRNS Marinus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLK Allakos	N/A	6.08	6.08
GEMP Gemphire Therapeutics	N/A	0.67	0.67
HILS Hillstream BioPharma	N/A	3.01	3.01
MRNS Marinus Pharmaceuticals	N/A	1.66	1.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLK Allakos	84.64%
GEMP Gemphire Therapeutics	17.53%
HILS Hillstream BioPharma	13.36%
MRNS Marinus Pharmaceuticals	98.80%

Insider Ownership

Company	Insider Ownership
ALLK Allakos	16.12%
GEMP Gemphire Therapeutics	22.70%
HILS Hillstream BioPharma	30.24%
MRNS Marinus Pharmaceuticals	5.46%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLK Allakos	190	90.38 million	74.94 million	Optionable
GEMP Gemphire Therapeutics	9	14.87 million	N/A	Not Optionable
HILS Hillstream BioPharma	1	17.60 million	12.28 million	Not Optionable
MRNS Marinus Pharmaceuticals	110	55.22 million	52.20 million	Optionable

GEMP, MRNS, HILS, and ALLK Headlines

Recent News About These Companies

Marinus Pharmaceuticals CEO Scott Braunstein sells $167,530 in stock

February 11, 2025 | msn.com

Marinus Pharmaceuticals director sells shares worth $869

January 24, 2025 | msn.com

Marinus pharmaceuticals director sells shares for $864

January 24, 2025 | msn.com

Marinus Pharmaceuticals (MRNS) Upgraded to Buy: Here's What You Should Know

January 10, 2025 | zacks.com

SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates MRNS, RHE, SSY, CTV on Behalf of Shareholders

January 9, 2025 | stockhouse.com

Marinus Pharmaceuticals Inc (MRNS) Stock: Greater Than Its Current Valuation?

January 7, 2025 | bovnews.comB

MARINUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Marinus Pharmaceuticals, Inc. - MRNS

January 6, 2025 | businesswire.com

Immedica Pharma to Acquire Marinus Pharmaceuticals in $151 Million Deal

January 4, 2025 | msn.com

Marinus (MRNS) Gets a Hold from Truist Financial

January 4, 2025 | markets.businessinsider.com

Marinus Pharmaceuticals Inc (MRNS) Stock: Beyond the Surface of Its Performance?

January 4, 2025 | bovnews.comB

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Marinus Pharmaceuticals, Inc. Buyout

January 2, 2025 | markets.businessinsider.com

Marinus Pharmaceuticals to be acquired by Immedica for 55c per share

January 1, 2025 | finance.yahoo.com

Marinus Pharmaceuticals Inc (MRNS) Stock: Understanding Its Underlying Value

December 31, 2024 | bovnews.comB

Marinus Pharma to Be Acquired by Immedica in $30 Million Deal

December 31, 2024 | marketwatch.com

Immedica to buy rare disease drugmaker Marinus for $151 million

December 31, 2024 | chicagobusiness.comC

Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc.

December 31, 2024 | finance.yahoo.com

Immedica to buy Marinus Pharmaceuticals, stock rises 4%

December 31, 2024 | msn.com

Marinus Pharma Agrees To $151 Million Acquisition By Immedica: Shares Surge Over 40%

December 30, 2024 | benzinga.com

MRNS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Marinus Pharmaceuticals, Inc. Is Fair to Shareholders

December 30, 2024 | businesswire.com

Shareholder Alert: Ademi LLP Investigates Whether Marinus Pharmaceuticals, Inc. Is Obtaining a Fair Price for Its Public Shareholders

December 30, 2024 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GEMP, MRNS, HILS, and ALLK Company Descriptions

Allakos NASDAQ:ALLK

Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.

Gemphire Therapeutics NASDAQ:GEMP

Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and nonalcoholic fatty liver disease (NAFLD/NASH). The company is developing gemcabene, a novel, once-daily, and oral therapy for dyslipidemia conditions where patients are unable to reach their lipid lowering goals, including patients already receiving maximally tolerated statin therapy. It also completed three Phase IIb clinical trials for gemcabene in homozygous familial hypercholesterolemia (HoFH) and hypercholesterolemia, including heterozygous familial hypercholesterolemic (HeFH) and atherosclerotic cardiovascular disease (ASCVD) patients on maximally tolerated statins, and severe hypertriglyceridemia (SHTG). The company was founded in 2008 and is headquartered in Livonia, Michigan.

Hillstream BioPharma NASDAQ:HILS

$1.63 -0.05 (-2.98%)

As of 07/16/2025

Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) and targeted immuno-oncology novel biologics for the treatment drug resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-3215, an anti-HER2 monoclonal antibody candidate; and HSB-1940, a Quatrabody that is a proprietary IO biologic in development targeting PD-1. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.

Marinus Pharmaceuticals NASDAQ:MRNS

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time